[NEW PODCAST] Exploring the FDA's Draft Guidance on Psychedelic Drug Research
Unlocking New Horizons
The FDA recently published a first-ever draft guidance on clinical development requirements for psychedelic drugs.
Join Altasciences’ panel of experts as they provide an in-depth review of the guidance and valuable insights into the areas where further methodological adaptations to study designs may be necessary. These adaptations play a pivotal role in accurately assessing the safety, pharmacology, and efficacy of groundbreaking psychedelic compounds developed for specific medical applications.
You may also be interested in the following:
• Webpage: CNS Drug Development Solutions
• Scientific Journal: Challenges Associated with Schedule I Therapeutic Development
• Webinar: Practical Approaches to Conducting Early Clinical Trials with Psychedelics